Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.

Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Bühler A, Döhner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M.

Leukemia. 2012 Dec;26(12):2549-52. doi: 10.1038/leu.2012.129. Epub 2012 May 15. No abstract available.

PMID:
22584787
2.

Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.

Gritti G, Reda G, Maura F, Piciocchi A, Baldini L, Molica S, Neri A, Cortelezzi A.

Leuk Lymphoma. 2012 Mar;53(3):424-9. doi: 10.3109/10428194.2011.623258. Epub 2012 Jan 5.

PMID:
21919823
3.

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.

Montillo M, Tedeschi A, Petrizzi VB, Ricci F, Crugnola M, Spriano M, Spedini P, Ilariucci F, Uziel L, Attolico I, Vismara E, De Blasio A, Zaccaria A, Morra E.

Blood. 2011 Oct 13;118(15):4079-85. doi: 10.1182/blood-2011-05-351833. Epub 2011 Jul 19.

4.

Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas.

Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M.

Eur J Haematol. 1997 Nov;59(5):327-8. No abstract available.

PMID:
9414645
5.

Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.

Smolej L, Doubek M, Panovská A, Simkovič M, Brychtová Y, Belada D, Motyčková M, Mayer J.

Leuk Res. 2012 Oct;36(10):1278-82. doi: 10.1016/j.leukres.2012.07.005. Epub 2012 Jul 25.

PMID:
22840362
6.

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.

J Clin Oncol. 2007 Mar 20;25(9):1114-20. Epub 2007 Feb 12. Erratum in: J Clin Oncol. 2008 Feb 10;26(5):820.

PMID:
17296974
7.

Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.

Krejci M, Doubek M, Brychtova Y, Stehlikova O, Chovancova J, Tichy B, Francova HS, Navratil M, Tomiska M, Horky O, Pospisilova S, Mayer J.

Ann Hematol. 2013 Jan;92(2):249-54. doi: 10.1007/s00277-012-1579-y. Epub 2012 Sep 27.

PMID:
23014659
8.

Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.

Hendry L, Bowen A, Matutes E, Swansbury J, Catovsky D.

Leuk Lymphoma. 2004 May;45(5):945-50.

PMID:
15291353
9.

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG.

Blood. 2011 Aug 25;118(8):2085-93. doi: 10.1182/blood-2011-03-341032. Epub 2011 Jun 13.

10.

High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.

Majolino I, Ladetto M, Locasciulli A, Drandi D, Benedetti F, Gallamini A, Chisesi T, De Blasio A, Boccadoro M, Tarella C.

Med Oncol. 2006;23(3):359-68.

PMID:
17018893
11.

A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.

Flowers CR, Brown JR, Rosenthal H, Stock W, Katzen HI, Cohen JB, Sinha R, Lakhanpal S, Leis JF, Waller EK, Jaye DL.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):694-8. doi: 10.1016/j.clml.2015.07.640. Epub 2015 Aug 5.

PMID:
26385641
12.

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.

Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A.

J Clin Oncol. 2005 Oct 1;23(28):7024-31. Epub 2005 Sep 6.

PMID:
16145065
13.

Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

Elter T, Kilp J, Borchmann P, Schulz H, Hallek M, Engert A.

Haematologica. 2009 Jan;94(1):150-2. doi: 10.3324/haematol.13379. Epub 2008 Nov 10. No abstract available.

14.

Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.

Ferrajoli A, Wierda WG, LaPushin R, O'Brien SM, Faderl S, Browning ML, Keating MJ.

Eur J Haematol. 2008 Apr;80(4):296-8. doi: 10.1111/j.1600-0609.2007.01023.x. Epub 2007 Dec 21.

PMID:
18182081
16.
17.

Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.

Bezares RF, Stemelin G, Diaz A, Argentieri D, Zubiaur EL, Garay G, Bartomioli M, Ryser R, Milone G.

Leuk Lymphoma. 2011 Oct;52(10):1936-41. doi: 10.3109/10428194.2011.584991. Epub 2011 Jun 30.

PMID:
21718136
18.

Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study.

Kowal M, Dmoszyńska A, Lewandowski K, Hellmann A, Wegrzyn J, Skotnicki AB, Wołowiec D, Kuliczkowski K, Piszcz J, Kłoczko J, Roznowski K, Komarnicki M.

Leuk Lymphoma. 2004 Jun;45(6):1159-65. Review.

PMID:
15359995
19.

Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy.

Orlandi EM, Baldanti F, Citro A, Pochintesta L, Gatti M, Lazzarino M.

Haematologica. 2008 Nov;93(11):1758-60. doi: 10.3324/haematol.13265. Epub 2008 Sep 11. No abstract available.

20.

Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.

Schiavone EM, De Simone M, Palmieri S, Annunziata M, Pocali B, Copia C, D'Amico MR, Vecchio LD, Ferrara F.

Eur J Haematol. 2003 Jul;71(1):23-8.

PMID:
12801295

Supplemental Content

Support Center